Effect of shRNA targeting mouse CD99L2 gene in a murine B cell lymphoma in vitro and in vivo

Liu,Fang; Zhang,Gong; Liu,Fanrong; Zhou,Xinhua; Chen,Xiaoyan; Han,Xiqun; Wu,Ziqing; Zhao,Tong

doi:10.3892/or.2013.2244

Effect of shRNA targeting mouse CD99L2 gene in a murine B cell lymphoma in vitro and in vivo

Authors:
- Fang Liu
- Gong Zhang
- Fanrong Liu
- Xinhua Zhou
- Xiaoyan Chen
- Xiqun Han
- Ziqing Wu
- Tong Zhao
View Affiliations

Affiliations: Department of Pathology, School of Basic Medical Science, Southern Medical University, Guangzhou 510515, P.R. China
Published online on: January 18, 2013 https://doi.org/10.3892/or.2013.2244
Pages: 1405-1414

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mouse CD99 antigen-like 2 (mCD99L2) has previously been confirmed to be expressed in murine B lymphoma (A20) cells by our group. The present study aimed to establish a mCD99L2‑downregulated A20 cell line and to investigate the effect of shRNA targeting mCD99L2 in A20 cells in vitro and in vivo. Four pLenti6/mCD99L2 expression vectors containing the mCD99L2 shRNA-expressing cassette were constructed, transfected into A20 cells and stable mCD99L2-downregulated A20 subclones, termed A20-mCD99L2- cells, were established and identified by quantitative PCR and western blot analysis. Light and transmission electron microscopy, MTT assay, flow cytometry and immunofluorenscence labeling were used to observe the morphological, biological and phenotypic characteristics in vitro. Some of the A20-mCD99L2- cells exhibited H/RS‑cell like morphology, a decreased proliferative ability, a prolonged G2 phase and increased CD30 and CD15 expression. Upon injecting cells into nude or immunocompetent BALB/c mice, tumorigenesis, tumor growth, morphology and phenotypes in vivo were observed. A20-mCD99L2- cells induced tumors in nude and BALB/c mice, but with less potency in the latter compared with the controls. Similar morphological, biological and phenotypic characteristics were observed in the A20-mCD99L2- cell-induced tumors as those in vitro. Several cytokines including CD30T, IL-12p40/p70, IL-3, IFN-γ, CXCL16, MIP-1α and CD40 were upregulated following mCD99L2 downregulation when detected using antibody arrays. The results from western blot analysis indicated that the regulation of mCD99L2 expression may involve the activated nuclear factor-κB pathway in the murine B lymphoma cells. The present study provides data for further investigation into the mCD99L2 gene in tumor cells.

View Figures

View References

1	Levy R, Dilley J, Fox RI, et al: A human thymusleukemia antigen defined by hybridoma monoclonal antibodies. Proc Natl Acad Sci USA. 76:6552–6556. 1979. View Article : Google Scholar : PubMed/NCBI
2	Bernard G, Raimondi V, Alberti I, et al: CD99 (E2) up-regulates alpha4beta1-dependent T cell adhesion to inflamed vascular endothelium under flow conditions. Eur J Immunol. 30:3061–3065. 2000. View Article : Google Scholar : PubMed/NCBI
3	Schenkel AR, Mamdouh Z, Chen X, et al: CD99 plays a major role in the migration of monocytes through endothelial junctions. Nature Immunol. 3:143–150. 2002. View Article : Google Scholar : PubMed/NCBI
4	Tato CM, Joyce-Shaikh B, Banerjee A, et al: The myeloid receptor PILRβ mediates the balance of inflammatory responses through regulation of IL-27 production. PLoS One. 7:e316802012.
5	Park HJ, Byun D, Lee AH, et al: CD99-dependent expansion of myeloid-derived suppressor cells and attenuation of graft-versus-host disease. Mol Cells. 33:259–267. 2012. View Article : Google Scholar : PubMed/NCBI
6	Dworzak MN, Froschl G, Printz D, et al: CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease. Leukemia. 18:703–708. 2004. View Article : Google Scholar : PubMed/NCBI
7	Maitra A, Hansel DE, Argani P, et al: Global expression analysis of well-differentiated pancreatic endocrine neoplasms using oligonucleotide microarrays. Clin Cancer Res. 9:5988–5995. 2003.
8	Kang LC and Dunphy CH: Immunoreactivity of MIC2 (CD99) and terminal deoxynucleotidyl transferase in bone marrow clot and core specimens of acute myeloid leukemias and myelodysplastic syndromes. Arch Pathol Lab Med. 130:153–157. 2006.
9	Diwan AH, Skelton HG III, Horenstein MG, et al: Dermatofibrosarcoma protuberans and giant cell fibroblastoma exhibit CD99 positivity. J Cutan Pathol. 35:647–650. 2008. View Article : Google Scholar : PubMed/NCBI
10	Ramsay AD, Bates AW, Williams S, et al: Variable antigen expression in hepatoblastomas. Appl Immunohistochem Mol Morphol. 16:140–147. 2008. View Article : Google Scholar : PubMed/NCBI
11	Suh YH, Shin YK, Kook MC, et al: Cloning, genomic organization, alternative transcripts and expression analysis of CD99L2, a novel paralog of human CD99, and identification of evolutionary conserved motifs. Gene. 307:63–76. 2003. View Article : Google Scholar
12	Bixel MG, Petri B, Khandoga AG, et al: A CD99-related antigen on endothelial cells mediates neutrophil but not lymphocyte extravasation in vivo. Blood. 109:5327–5336. 2007. View Article : Google Scholar : PubMed/NCBI
13	Bixel MG, Li H, Petri B, et al: CD99 and CD99L2 act at the same site as, but independently of, PECAM-1 during leukocyte diapedesis. Blood. 116:1172–1184. 2010. View Article : Google Scholar : PubMed/NCBI
14	Kim KJ, Kanellopoulos-Langevin C, Merwin RM, et al: Establishment and characterization of BALB/c lymphoma lines with B cell properties. J Immunol. 122:549–554. 1979.PubMed/NCBI
15	Passineau MJ, Siegal GP, Everts M, et al: The natural history of a novel, systemic, disseminated model of syngeneic mouse B-cell lymphoma. Leuk Lymphoma. 46:1627–1638. 2005.PubMed/NCBI
16	Warncke M, Buchner M, Thaller G, et al: Control of the specificity of T cell-mediated anti-idiotype immunity by natural regulatory T cells. Cancer Immunol Immunother. 60:49–60. 2011. View Article : Google Scholar : PubMed/NCBI
17	Liu F, Zhang G, Zhou XH, et al: Immuno-characterization of mouse model similar to human diffuse large B cell lymphoma. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 18:655–659. 2010.(In Chinese).
18	Shen LJ, Fang WY, Xie SM, et al: Expression and cloning of mCD99L2 gene from mouse B lymphoma cell line A20 and construction of its eukaryotic expression vector. Nan Fang Yi Ke Da Xue Xue Bao. 26:144–149. 2006.(In Chinese).
19	Kim SH, Choi EY, Shin YK, et al: Generation of cells with Hodgkin’s and Reed-Sternberg phenotype through downregulation of CD99 (Mic2). Blood. 92:4287–4295. 1998.
20	Kim SH, Shin YK, Lee IS, et al: Viral latent membrane protein 1 (LMP-1)-induced CD99 down-regulation in B cells leads to the generation of cells with Hodgkin’s and Reed-Sternberg phenotype. Blood. 95:294–300. 2000.PubMed/NCBI
21	Huang X, Zhou X, Wang Z, et al: CD99 triggers upregulation of miR-9-modulated PRDM1/BLIMP1 in Hodgkin/Reed-Sternberg cells and induces redifferentiation. Int J Cancer. 131:E382–E394. 2012. View Article : Google Scholar : PubMed/NCBI
22	Burgess SC, Young JR, Baaten BJ, et al: Marek’s disease is a natural model for lymphomas overexpressing Hodgkin’s disease antigen (CD30). Proc Natl Acad Sci USA. 101:13879–13884. 2004.
23	Scotlandi K, Zuntini M, Manara MC, et al: CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity. Oncogene. 26:6604–6618. 2007. View Article : Google Scholar : PubMed/NCBI
24	Garcia JF, Camacho FI, Morente M, et al: Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood. 101:681–689. 2003. View Article : Google Scholar
25	Sánchez-Aguilera A, Montalbán C, de la Cueva P, et al: Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood. 108:662–668. 2006.PubMed/NCBI
26	Marafioti T, Hummel M, Foss HD, et al: Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood. 95:1443–1450. 2000.
27	Maggio E, van den Berg A, Diepstra A, et al: Chemokines, cytokines and their receptors in Hodgkin’s lymphoma cell lines and tissues. Ann Oncol. 13(Suppl 1): 52–56. 2002.
28	Skinnider BF and Mak TW: The role of cytokines in classical Hodgkin lymphoma. Blood. 99:4283–4297. 2002. View Article : Google Scholar : PubMed/NCBI
29	Steidl C, Connors JM and Gascoyne RD: Molecular pathogenesis of Hodgkin’s lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol. 29:1812–1826. 2011.
30	Aldinucci D, Olivo K, Lorenzon D, et al: The role of interleukin-3 in classical Hodgkin’s disease. Leuk Lymphoma. 46:303–311. 2005.
31	Niederkorn JY: Emerging concepts in CD8(+) T regulatory cells. Curr Opin Immunol. 20:327–331. 2008.
32	Lee IS, Kim SH, Song HG, et al: The molecular basis for the generation of Hodgkin and Reed-Sternberg cells in Hodgkin’s lymphoma. Int J Hematol. 77:330–335. 2003.
33	Hanamoto H, Nakayama T, Miyazato H, et al: Expression of CCL28 by Reed-Sternberg cells defines a major subtype of classical Hodgkin’s disease with frequent infiltration of eosinophils and/or plasma cells. Am J Pathol. 164:997–1006. 2004.PubMed/NCBI
34	Luft T, Luetjens P, Hochrein H, et al: IFN-alpha enhances CD40 ligand-mediated activation of immature monocyte-derived dendritic cells. Int Immunol. 14:367–380. 2002. View Article : Google Scholar : PubMed/NCBI
35	Meijer J, Ogink J, Kreike B, et al: The chemokine receptor CXCR6 and its ligand CXCL16 are expressed in carcinomas and inhibit proliferation. Cancer Res. 68:4701–4708. 2008. View Article : Google Scholar : PubMed/NCBI
36	Horie R, Watanabe T, Morishita Y, et al: Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells. Oncogene. 21:2493–2503. 2002. View Article : Google Scholar : PubMed/NCBI
37	Aldinucci D, Lorenzon D, Cattaruzza L, Pinto A, Gloghini A, Carbone A and Colombatti A: Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions. Int J Cancer. 122:769–776. 2008. View Article : Google Scholar : PubMed/NCBI
38	Schwarzer R and Jundt F: Notch and NF-κB signaling pathways in the biology of classical Hodgkin lymphoma. Curr Mol Med. 11:236–245. 2011.